Clinical trial
A Phase II Study of Candonilimab (AK104) Combined With Preoperative Chemotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
NCT05896787 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Candonilimab (AK104) Combined With Preoperative Chemotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2023
- Completion date
- August 1, 2026
- Enrollment
- 45 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.